AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties … Continue reading →

Blood and genomic testing are becoming preferable means of early cancer screening and detection Leaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and Guardant AnPac Bio-Medical’s testing features a database of more than 200,000 commercial … Continue reading →

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in … Continue reading →

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated  $1.4 … Continue reading →

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty … Continue reading →

Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patients AnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and … Continue reading →

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer … Continue reading →

AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021 Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over … Continue reading →

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties … Continue reading →